Emkay's research report on Sun Pharmaceutical Industries
"Sun Pharma Q1FY15 results (vs. expectations) - Revenue at Rs39.4bn (vs. Rs39.1bn), EBITDA at Rs17.3bn (vs. Rs15.1bn) and Adjusted PAT at Rs13.9bn (vs. Rs11.6bn)
US sales up by 14.4% yoy (up 7% to USD 389mn), despite decline in Taro sales (down 15% yoy) due to price protection charges. Domestic formulations were up 17% yoy
Expect steady growth momentum in the domestic formulations business; US growth to be steady driven by price increases in Taro portfolio and niche launches in FY16
We expect a top-line growth of 16% (CAGR) in FY14-16E. Margin is expected to be in the vicinity of 45% over the same period.
We have built in sales growth at a CAGR of 16% in FY14-16E, while we believe EBITDA margin will remain in the vicinity of 45-46%. We maintain a BUY, with a revised target price of Rs 928 (25x FY16E EPS of Rs 37.1)", says Emkay Global Financial Services research.
For all recommendations, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
